Latest Videos

Transperineal Mapping Biopsy: Does Technique Matter?

Nelson N. Stone, MD, Professor of Urology, Radiation Oncology, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai and at the Derald H. Ruttenberg Cancer Center at Mount Sinai School of Medicine in New York, discusses transperineal mapping biopsy (TPMB). He explains that treating a single quadrant as identified by MRI may leave unidentified clinically-significant prostate cancer behind. For focal therapy, Dr. Stone advocates for what he calls a unified approach using TPMB, which can be done under local anesthesia.

Read More

Managing Chronically Late Patients

Grand Rounds in Urology Contributing Editor Neil H. Baum, MD, Professor of Urology at Tulane Medical School, offers advice on managing chronically late patients. As most physicians know, late patients create significant scheduling challenges, decrease staff efficiency, and increase stress levels. Dr. Baum suggests creating a written policy addressing chronic lateness that explains the cascading problems for doctors and staff when patients fail to arrive on time, and requesting patients arrive early to complete necessary paperwork or pay for their visit. He also advises seeing chronically late patients at the end of the day or rescheduling them which will serve to reinforce the message. Of course, it is valuable to understand reasons for occasional lateness like older patients who may be dependent on a family member for transportation. Dr. Baum underscores the importance of being an on-time physician if asking the same of patients. Inevitably schedule delays happen. If you’re running late, send a staff person out to the waiting room to explain and give patients an option to reschedule. Contrary to popular belief, charging patients for lateness is ineffective and the fees are hard to collect. Likewise, overbooking patients in an effort to fit them around late arrivals is more likely to create additional delays for physicians and staff.

Read More

Industry Perspective – From Science to Clinical Utility: The Role of Cxbladder in the Diagnosis and Management of Bladder Cancer

In this 17-minute video sponsored by Pacific Edge Diagnostics, Tamer Aboushwareb, MD, PhD, Vice President of Medical Affairs for Pacific Edge Diagnostics, discusses the role of the Cxbladder test in improving the diagnosis, treatment, and management of bladder cancer, including lowering costs, improving physician workflow, and helping to avoid invasive cystoscopic procedures.

Read More

Genetic Testing for Identifying Who is at Risk of Prostate Cancer and Lethal Cancer

Jianfeng Xu, MD, DrPH, Vice President of Translational Research at NorthShore University HealthSystem (NorthShore), the Ellrodt-Schweighauser Family Chair of Cancer Genomic Research, Director of the Program for Personalized Cancer Care (PPCC) at NorthShore, and a Research Professor at the University of Chicago Pritzker School of Medicine, discusses the role of genetic testing in prostate cancer risk identification. Dr. Xu discusses who is at elevated risk for prostate cancer, the relationship among three inherited risk factors (family history [FH], monogenic rare pathogenic mutations [RPMs], and polygenic genetic risk score [GRS]), the idea that monogenic and polygenic may be tested at the same time, key challenges for germline testing, and the improvement of current guidelines for prostate cancer early detection.

Read More

Brachytherapy: The Royal Flush of Radiation Treatment for Men with High-Risk Prostate Cancer

Mira Keyes, MD, FRCPC, a Clinical Professor at the University of British Columbia (UBC) and a radiation oncologist at the Vancouver Centre of the British Columbia Cancer Agency (BCCA), discusses the benefits of prostate brachytherapy (PB) for men with high- and very high-risk prostate cancer. Dr. Keyes explains PB has excellent long-term outcomes (with the best cure rates of all radiation therapy [RT] treatments), requires less androgen deprivation therapy (ADT), has less downstream toxicity and lower cost than alternatives, calling it a “royal flush” treatment when used as a boost with external beam radiation therapy (EPRT).

Read More

Join the GRU Community

- Why Join? -